Shire Urges Fed. Circ. To Block Actavis' Generic Lialda

Law360, New York (August 8, 2013, 7:59 PM EDT) -- Shire PLC on Wednesday pressed the Federal Circuit to affirm the validity of a patent covering inflammatory bowel disease drug Lialda and declare that Actavis Inc. committed infringement in trying to launch a generic version.

In an opening brief, Ireland-based Shire urged the appeals court to uphold a May decision in which a Florida federal judge found Actavis had treaded impermissibly on two claims of U.S. Patent Number 6,773,720, which protects a controlled-release formulation for mesalamine.

The composition patent is a key obstacle to launching a copycat...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.